Search

Your search keyword '"Montano-Loza, Aldo J."' showing total 707 results
Start Over Author "Montano-Loza, Aldo J."
707 results on '"Montano-Loza, Aldo J."'

3. Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis

Author

Lam, Laurent, Soret, Pierre-Antoine, Lemoinne, Sara, Hansen, Bettina, Hirschfield, Gideon, Gulamhusein, Aliya, Montano-Loza, Aldo J., Lytvyak, Ellina, Parés, Albert, Olivas, Ignasi, Londono, Maria-Carlota, Rodríguez-Tajes, Sergio, Eaton, John E., Osman, Karim T., Schramm, Christoph, Sebode, Marcial, Lohse, Ansgar W., Dalekos, George, Gatselis, Nikolaos, Nevens, Frederik, Cazzagon, Nora, Zago, Alessandra, Russo, Francesco Paolo, Floreani, Annarosa, Abbas, Nadir, Trivedi, Palak, Thorburn, Douglas, Saffioti, Francesca, Barkai, Laszlo, Roccarina, Davide, Calvaruso, Vicenza, Fichera, Anna, Delamarre, Adèle, Sobenko, Natalia, Villamil, Alejandra Maria, Medina-Morales, Esli, Bonder, Alan, Patwardhan, Vilas, Rigamonti, Cristina, Carbone, Marco, Invernizzi, Pietro, Cristoferi, Laura, van der Meer, Adriaan, de Veer, Rozanne, Zigmond, Ehud, Yehezkel, Eyal, Kremer, Andreas E., Deibel, Ansgar, Bruns, Tony, Große, Karsten, Wetten, Aaron, Dyson, Jessica Katharine, Jones, David, Levy, Cynthia, Tanaka, Atsushi, Dumortier, Jérôme, Pageaux, Georges-Philippe, de Lédinghen, Victor, Carrat, Fabrice, Chazouillères, Olivier, and Corpechot, Christophe

Published
2024
Full Text
View/download PDF

4. Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis

Author

Roberts, Surain B., Choi, Woo Jin, Worobetz, Lawrence, Vincent, Catherine, Flemming, Jennifer A., Cheung, Angela, Qumosani, Karim, Swain, Mark, Grbic, Dusanka, Ko, Hin Hin, Peltekian, Kevork M., Abrahamyan, Lusine, Saini, Monika, Tirona, Kattleya, Aziz, Bishoi, Lytvyak, Ellina, Invernizzi, Pietro, Ponsioen, Cyriel Y., Bruns, Tony, Cazzagon, Nora, Lindor, Keith, Dalekos, George N., Gatselis, Nikolaos K., Verhelst, Xavier, Floreani, Annarosa, Corpechot, Christophe, Mayo, Marlyn J., Levy, Cynthia, Londoño, Maria-Carlota, Battezzati, Pier M., Pares, Albert, Nevens, Frederik, van der Meer, Adriaan, Kowdley, Kris V., Trivedi, Palak J., Lleo, Ana, Thorburn, Douglas, Carbone, Marco, Selzner, Nazia, Gulamhusein, Aliya F., Janssen, Harry LA., Montano-Loza, Aldo J., Mason, Andrew L., Hirschfield, Gideon M., and Hansen, Bettina E.

Published
2024
Full Text
View/download PDF

5. Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation

Author

Montano-Loza, Aldo J., Lytvyak, Ellina, Hirschfield, Gideon, Hansen, Bettina E., Ebadi, Maryam, Berney, Thierry, Toso, Christian, Magini, Giulia, Villamil, Alejandra, Nevens, Frederik, Van den Ende, Natalie, Pares, Albert, Ruiz, Pablo, Terrabuio, Débora, Trivedi, Palak J., Abbas, Nadir, Donato, Maria Francesca, Yu, Lei, Landis, Charles, Dumortier, Jérôme, Dyson, Jessica Katharine, van der Meer, Adriaan J., de Veer, Rozanne, Pedersen, Mark, Mayo, Marlyn, Manns, Michael P., Taubert, Richard, Kirchner, Theresa, Belli, Luca S., Mazzarelli, Chiara, Stirnimann, Guido, Floreani, Annarosa, Cazzagon, Nora, Russo, Francesco Paolo, Burra, Patrizia, Zigmound, Udi, Houri, Inbal, Carbone, Marco, Mulinacci, Giacomo, Fagiuoli, Stefano, Pratt, Daniel Stephan, Bonder, Alan, Schiano, Thomas D., Haydel, Brandy, Lohse, Ansgar, Schramm, Christoph, Rüther, Darius, Casu, Stefania, Verhelst, Xavier, Beretta-Piccoli, Benedetta Terziroli, Robles, Mercedes, Mason, Andrew L., and Corpechot, Christophe

Published
2024
Full Text
View/download PDF

6. Treatment response and clinical event-free survival in autoimmune hepatitis: A Canadian multicentre cohort study

Author

Plagiannakos, Christina G., Hirschfield, Gideon M., Lytvyak, Ellina, Roberts, Surain B., Ismail, Marwa, Gulamhusein, Aliya F., Selzner, Nazia, Qumosani, Karim M., Worobetz, Lawrence, Hercun, Julian, Vincent, Catherine, Flemming, Jennifer A., Swain, Mark G., Cheung, Angela, Chen, Tianyan, Grbic, Dusanka, Peltekain, Kevork, Mason, Andrew L., Montano-Loza, Aldo J., and Hansen, Bettina E.

Published
2024
Full Text
View/download PDF

7. Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis

Author

van Gerven, N., van Erpecum, K., Ouden, J den, Brouwer, J., Vrolijk, J., Gevers, T.J., Drenth, J., Guichelaar, M., Bouma, G., Schreuder, T.C.M.A., van der Wouden, E.J., Baak, L.C., Stadhouders, P., Klemt-Kropp, M., Verhagen, M., Bhalla, A., Kuijvenhoven, J., Almasio, P., Alvarez, F., Andrade, R., Arikan, C., Assis, D., Bardou-Jacquet, E., Biewenga, M., Cancado, E., Cazzagon, N., Chazouillères, O., Colloredo, G., Cuarterolo, M., Dalekos, G., Debray, D., Robles-Díaz, M., Dyson, J., Efe, C., Engel, B., Ferri, S., Fontana, R., Gatselis, N., Gerussi, A., Halilbasic, E., Halliday, N., Heneghan, M., Hirschfield, G., van Hoek, B., Hørby Jørgensen, M., Indolfini, G., Iorio, R., Invernizzi, P., Jeong, S., Jones, D., Kelly, D., Kerkar, N., Lacaille, F., Lammert, C., Leggett, B., Lenzi, M., Levy, C., Liberal, R., Lleo, A., Lohse, A., Lopez, S. Ines, de Martin, E., McLin, V., Mieli-Vergani, G., Milkiewicz, P., Mohan, N., Muratori, L., Nebbia, G., van Nieuwkerk, C., Oo, Y., Ortega, A., Páres, A., Pop, T., Pratt, D., Purnak, T., Ranucci, G., Rushbrook, S., Schramm, C., Stättermayer, A., Swain, M., Tanaka, A., Taubert, R., Terrabuio, D., Terziroli, B., Trauner, M., Valentino, P., van den Brand, F., Vergani, D., Villamil, A., Wahlin, S., Ytting, H., Zachou, K., Zeniya, M., Colapietro, Francesca, Maisonneuve, Patrick, Lytvyak, Ellina, Beuers, Ulrich, Verdonk, Robert C., van der Meer, Adriaan J., van Hoek, Bart, Kuiken, Sjoerd D., Brouwer, Johannes T., Muratori, Paolo, Aghemo, Alessio, Carella, Francesco, van den Berg, Ad P., Zachou, Kalliopi, Dalekos, George N., Di Zeo-Sánchez, Daniel E., Robles, Mercedes, Andrade, Raul J., Montano-Loza, Aldo J., van den Brand, Floris F., Slooter, Charlotte D., Macedo, Guilherme, Liberal, Rodrigo, de Boer, Ynto S., and Lleo, Ana

Published
2024
Full Text
View/download PDF

8. Sarcopenia and frailty in decompensated cirrhosis

Author

Tandon, Puneeta, Montano-Loza, Aldo J, Lai, Jennifer C, Dasarathy, Srinivasan, and Merli, Manuela

Subjects
Digestive Diseases, Clinical Research, Prevention, Chronic Liver Disease and Cirrhosis, Aging, Liver Disease, 6.7 Physical, 2.1 Biological and endogenous factors, Evaluation of treatments and therapeutic interventions, Aetiology, Oral and gastrointestinal, Musculoskeletal, Disease Progression, Frailty, Humans, Liver Cirrhosis, Preventive Health Services, Sarcopenia, Body composition, Muscle mass, Muscle function, Survival, End-stage liver disease, Liver transplant, Computed tomography, Clinical Sciences, Public Health and Health Services, Gastroenterology & Hepatology
Abstract

In patients with decompensated cirrhosis, sarcopenia and frailty are prevalent. Although several definitions exist for these terms, in the field of hepatology, sarcopenia has commonly been defined as loss of muscle mass, and frailty has been broadly defined as the phenotypic manifestation of the loss of muscle function. Prompt recognition and accurate assessment of these conditions are critical as they are both strongly associated with morbidity, mortality, poor quality of life and worse post-liver transplant outcomes in patients with cirrhosis. In this review, we describe the complex pathophysiology that underlies the clinical phenotypes of sarcopenia and frailty, their association with decompensation, and provide an overview of tools to assess these conditions in patients with cirrhosis. When available, we highlight data focusing on patients with acutely decompensated cirrhosis, such as inpatients, as this is an area of unmet clinical need. Finally, we discuss management strategies to reverse and/or prevent the development of sarcopenia and frailty, which include adequate nutritional intake of calories and protein, as well as regular exercise of at least moderate intensity, with a mix of aerobic and resistance training. Key knowledge gaps in our understanding of sarcopenia and frailty in decompensated cirrhosis remain, including best methods to measure muscle mass and function in the inpatient setting, racial/ethnic variation in the development and presentation of sarcopenia and frailty, and optimal clinical metrics to assess response to therapeutic interventions that translate into a reduction in adverse outcomes associated with these conditions.

Published
2021

9. Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study

Author

Eksteen, Bertus, Bowlus, Christopher L, Montano‐Loza, Aldo J, Lefebvre, Eric, Fischer, Laurent, Vig, Pamela, Martins, Eduardo Bruno, Ahmad, Jawad, Yimam, Kidist K, Pockros, Paul J, Feld, Jordan J, Minuk, Gerald, and Levy, Cynthia

Subjects
Rare Diseases, Clinical Research, Patient Safety, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adolescent, Adult, Aged, Alkaline Phosphatase, Biomarkers, Canada, Cholangitis, Sclerosing, Female, Humans, Imidazoles, Liver Function Tests, Male, Middle Aged, Sulfoxides, Treatment Outcome, United States, Young Adult
Abstract

Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease with no approved treatments. C-C chemokine receptor types 2 and 5 (CCR2/CCR5) play an important role in inflammation and fibrosis and are potential therapeutic targets for PSC. We evaluated the efficacy and safety of cenicriviroc (CVC), a dual antagonist of CCR2 and CCR5, for the treatment of PSC. This was a single-arm, open-label, exploratory study of CVC in adults with a clinical diagnosis of PSC, serum alkaline phosphatase (ALP) ≥1.5 times the upper limit of normal (ULN), with or without inflammatory bowel disease, across eight sites in the United States and Canada. The primary endpoint was percent change in ALP over 24 weeks; key secondary efficacy endpoints were proportion of participants who achieved ALP normalization and overall response (decrease to

Published
2021

11. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases

Author

Lynch, Kate D, Chapman, Roger W, Keshav, Satish, Montano-Loza, Aldo J, Mason, Andrew L, Kremer, Andreas E, Vetter, Marcel, de Krijger, Manon, Ponsioen, Cyriel Y, Trivedi, Palak, Hirschfield, Gideon, Schramm, Christoph, Liu, Chung Heng, Bowlus, Christopher L, Estes, Derek J, Pratt, Daniel, Hedin, Charlotte, Bergquist, Annika, de Vries, Annemarie C, van der Woude, C Janneke, Yu, Lei, Assis, David N, Boyer, James, Ytting, Henriette, Hallibasic, Emina, Trauner, Michael, Marschall, Hanns-Ulrich, Daretti, Luigi M, Marzioni, Marco, Yimam, Kidist K, Perin, Nicola, Floreani, Annarosa, Beretta-Piccoli, Benedetta Terziroli, Rogers, Jennifer K, Group, International Primary Sclerosing Cholangitis Study, and Levy, Cynthia

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Digestive Diseases - (Gallbladder), Liver Disease, Digestive Diseases, Inflammatory Bowel Disease, Autoimmune Disease, Chronic Liver Disease and Cirrhosis, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Oral and gastrointestinal, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Child, Cholangitis, Sclerosing, Gastrointestinal Agents, Humans, Inflammatory Bowel Diseases, Integrins, Liver Function Tests, Middle Aged, Retrospective Studies, Young Adult, Cholestatic Liver Disease, Ulcerative Colitis, Crohn's Disease, Integrin alpha4beta7, International Primary Sclerosing Cholangitis Study Group, Crohn’s Disease, Gastroenterology & Hepatology, Clinical sciences
Abstract

Background & aimsGut-homing lymphocytes that express the integrin α4β7 and CCR9 might contribute to development of primary sclerosing cholangitis (PSC). Vedolizumab, which blocks the integrin α4β7, is used to treat patients with inflammatory bowel diseases (IBD), but there are few data on its efficacy in patients with PSC. We investigated the effects of vedolizumab in a large international cohort of patients with PSC and IBD.MethodsWe collected data from European and North American centers participating in the International PSC Study Group from patients with PSC and IBD who received at least 3 doses of vedolizumab (n = 102; median vedolizumab treatment duration, 412 days). Demographic and clinical data were collected from baseline and during the follow-up period (until liver transplantation, death, or 56 days after the final vedolizumab infusion). We analyzed overall changes in biochemical features of liver and proportions of patients with reductions in serum levels of alkaline phosphatase (ALP) of 20% or more, from baseline through last follow-up evaluation. Other endpoints included response of IBD to treatment (improved, unchanged, or worsened, judged by the treating clinician, as well as endoscopic score) and liver-related outcomes.ResultsIn the entire cohort, the median serum level of ALP increased from 1.54-fold the upper limit of normal at baseline to 1.64-fold the upper limit of normal at the last follow-up examination (P = .018); serum levels of transaminases and bilirubin also increased by a small amount between baseline and the last follow-up examination. Serum levels of ALP decreased by 20% or more in 21 patients (20.6%); only the presence of cirrhosis (odds ratio, 4.48; P = .019) was independently associated with this outcome. Of patients with available endoscopic data, 56.8% had a response of IBD to treatment. Liver-related events occurred in 21 patients (20.6%), including bacterial cholangitis, cirrhosis decompensation, or transplantation.ConclusionsIn an analysis of patients with PSC and IBD in an international study group, we found no evidence for a biochemical response to vedolizumab, although serum level of ALP decreased by 20% or more in a subset of patients. Vedolizumab appears to be well tolerated and the overall response of IBD was the same as expected for patients without PSC.

Published
2020

13. A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation

Author

Carey, Elizabeth J, Lai, Jennifer C, Sonnenday, Christopher, Tapper, Elliot B, Tandon, Puneeta, Duarte‐Rojo, Andres, Dunn, Michael A, Tsien, Cynthia, Kallwitz, Eric R, Ng, Vicky, Dasarathy, Srinivasan, Kappus, Matthew, Bashir, Mustafa R, and Montano‐Loza, Aldo J

Subjects
Digestive Diseases, Chronic Liver Disease and Cirrhosis, Liver Disease, Aging, Clinical Research, Organ Transplantation, Transplantation, Prevention, Evaluation of treatments and therapeutic interventions, 6.7 Physical, Musculoskeletal, Oral and gastrointestinal, Good Health and Well Being, Canada, Clinical Decision-Making, Expert Testimony, Female, Humans, Liver Cirrhosis, Liver Transplantation, Male, Practice Guidelines as Topic, Preoperative Care, Sarcopenia, United States, Medical Biochemistry and Metabolomics, Clinical Sciences, Immunology, Gastroenterology & Hepatology
Abstract

Loss of muscle mass and function, or sarcopenia, is a common feature of cirrhosis and contributes significantly to morbidity and mortality in this population. Sarcopenia is a main indicator of adverse outcomes in this population, including poor quality of life, hepatic decompensation, mortality in patients with cirrhosis evaluated for liver transplantation (LT), longer hospital and intensive care unit stay, higher incidence of infection following LT, and higher overall health care cost. Although it is clear that muscle mass is an important predictor of LT outcomes, many questions remain, including the best modality for assessing muscle mass, the optimal cut-off values for sarcopenia, the ideal timing and frequency of muscle mass assessment, and how to best incorporate the concept of sarcopenia into clinical decision making. For these reasons, we assembled a group of experts to form the North American Working Group on Sarcopenia in Liver Transplantation to use evidence from the medical literature to address these outstanding questions regarding sarcopenia in LT. We believe sarcopenia assessment should be considered in all patients with cirrhosis evaluated for liver transplantation. Skeletal muscle index (SMI) assessed by computed tomography constitutes the best-studied technique for assessing sarcopenia in patients with cirrhosis. Cut-off values for sarcopenia, defined as SMI < 50 cm2 /m2 in male and < 39 cm2 /m2 in female patients, constitute the validated definition for sarcopenia in patients with cirrhosis. Conclusion: The management of sarcopenia requires a multipronged approach including nutrition, exercise, and additional pharmacological therapy as deemed necessary. Future studies should evaluate whether recovery of sarcopenia with nutritional management in combination with an exercise program is sustainable as well as how improvement in muscle mass might be associated with improvement in clinical outcomes.

Published
2019

14. Sarcopenia Predicts Post-transplant Mortality in Acutely Ill Men Undergoing Urgent Evaluation and Liver Transplantation.

Author

Kuo, Selena Z, Ahmad, Myra, Dunn, Michael A, Montano-Loza, Aldo J, Carey, Elizabeth J, Lin, Shezhang, Moghe, Akshata, Chen, Hui-Wei, Ebadi, Maryam, and Lai, Jennifer C

Subjects
Muscle, Skeletal, Humans, Liver Cirrhosis, Acute Disease, Critical Illness, Postoperative Complications, Treatment Outcome, Liver Transplantation, Proportional Hazards Models, Risk Factors, Sex Factors, Adult, Middle Aged, Inpatients, Female, Male, Sarcopenia, End Stage Liver Disease, Clinical Research, Digestive Diseases, Transplantation, Genetics, Organ Transplantation, Chronic Liver Disease and Cirrhosis, Liver Disease, Good Health and Well Being, Medical and Health Sciences, Surgery
Abstract

BackgroundWe examined the association between sarcopenia and post-transplant mortality in acutely ill inpatients with cirrhosis who underwent urgent liver transplantation.MethodsIncluded were inpatients at 4 centers who were urgently listed as nonstatus 1 and transplanted from 2005 to 2017 with an abdominal computed tomography scan 48 cm/m experienced higher rates of death at 1 year (86% versus 95%) and 3 years (73% versus 95%) (Log-rank P = 0.01). In MELD-adjusted analysis, sarcopenia was strongly associated with post-transplant mortality (HR = 4.39, 95% CI 1.49-12.97). Among women, 35% died. Median SMI was similar in women who died versus survived (45 versus 44 cm/m). SMI was not associated with post-transplant mortality (HR = 1.02, 95% CI 0.96-1.09). Optimal search did not identify any SMI cutoff that predicted post-transplant mortality.ConclusionsAmong patients who underwent urgent inpatient evaluation and liver transplantation, we identified an SMI cutoff value of 48 cm/m to predict post-transplant mortality in men. Our data support the use of SMI as a tool to capture the impact of muscle depletion on post-transplant mortality in acutely ill men with cirrhosis undergoing urgent liver transplantation.

Published
2019

15. Frailty in liver transplantation: An expert opinion statement from the American Society of Transplantation Liver and Intestinal Community of Practice

Author

Lai, Jennifer C, Sonnenday, Christopher J, Tapper, Elliot B, Duarte-Rojo, Andres, Dunn, Michael A, Bernal, William, Carey, Elizabeth J, Dasarathy, Srinivasan, Kamath, Binita M, Kappus, Matthew R, Montano-Loza, Aldo J, Nagai, Shunji, and Tandon, Puneeta

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Liver Disease, Transplantation, Clinical Research, Chronic Liver Disease and Cirrhosis, Digestive Diseases, Organ Transplantation, Oral and gastrointestinal, Activities of Daily Living, Adult, Algorithms, Child, Frailty, Humans, Intestines, Liver Transplantation, Practice Patterns, Physicians', Societies, Medical, clinical research, practice, guidelines, liver transplantation, hepatology, nutrition, recipient selection, clinical research/practice, liver transplantation/hepatology, Medical and Health Sciences, Surgery, Clinical sciences, Immunology
Abstract

Frailty has emerged as a powerful predictor of outcomes in patients with cirrhosis and has inevitably made its way into decision making within liver transplantation. In an effort to harmonize integration of the concept of frailty among transplant centers, the AST and ASTS supported the efforts of our working group to develop this statement from experts in the field. Frailty is a multidimensional construct that represents the end-manifestation of derangements of multiple physiologic systems leading to decreased physiologic reserve and increased vulnerability to health stressors. In hepatology/liver transplantation, investigation of frailty has largely focused on physical frailty, which subsumes the concepts of functional performance, functional capacity, and disability. There was consensus that every liver transplant candidate should be assessed at baseline and longitudinally using a standardized frailty tool, which should guide the intensity and type of nutritional and physical therapy in individual liver transplant candidates. The working group agreed that frailty should not be used as the sole criterion for delisting a patient for liver transplantation, but rather should be considered one of many criteria when evaluating transplant candidacy and suitability. A road map to advance frailty in the clinical and research settings of liver transplantation is presented here.

Published
2019

18. Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis

Author

Corpechot, Christophe, Carrat, Fabrice, Gaouar, Farid, Chau, Frederic, Hirschfield, Gideon, Gulamhusein, Aliya, Montano-Loza, Aldo J., Lytvyak, Ellina, Schramm, Christoph, Pares, Albert, Olivas, Ignasi, Eaton, John E., Osman, Karim T., Dalekos, George, Gatselis, Nikolaos, Nevens, Frederik, Cazzagon, Nora, Zago, Alessandra, Russo, Francesco Paolo, Abbas, Nadir, Trivedi, Palak, Thorburn, Douglas, Saffioti, Francesca, Barkai, Laszlo, Roccarina, Davide, Calvaruso, Vicenza, Fichera, Anna, Delamarre, Adèle, Medina-Morales, Esli, Bonder, Alan, Patwardhan, Vilas, Rigamonti, Cristina, Carbone, Marco, Invernizzi, Pietro, Cristoferi, Laura, van der Meer, Adriaan, de Veer, Rozanne, Zigmond, Ehud, Yehezkel, Eyal, Kremer, Andreas E., Deibel, Ansgar, Dumortier, Jérôme, Bruns, Tony, Große, Karsten, Pageaux, Georges-Philippe, Wetten, Aaron, Dyson, Jessica, Jones, David, Chazouillères, Olivier, Hansen, Bettina, and de Lédinghen, Victor

Published
2022
Full Text
View/download PDF

21. Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation

Author

Montano-Loza, Aldo J., Ronca, Vincenzo, Ebadi, Maryam, Hansen, Bettina E., Hirschfield, Gideon, Elwir, Saleh, Alsaed, Mohamad, Milkiewicz, Piotr, Janik, Maciej K., Marschall, Hanns-Ulrich, Burza, Maria Antonella, Efe, Cumali, Calışkan, Ali Rıza, Harputluoglu, Murat, Kabaçam, Gökhan, Terrabuio, Débora, de Quadros Onofrio, Fernanda, Selzner, Nazia, Bonder, Alan, Parés, Albert, Llovet, Laura, Akyıldız, Murat, Arikan, Cigdem, Manns, Michael P., Taubert, Richard, Weber, Anna-Lena, Schiano, Thomas D., Haydel, Brandy, Czubkowski, Piotr, Socha, Piotr, Ołdak, Natalia, Akamatsu, Nobuhisa, Tanaka, Atsushi, Levy, Cynthia, Martin, Eric F., Goel, Aparna, Sedki, Mai, Jankowska, Irena, Ikegami, Toru, Rodriguez, Maria, Sterneck, Martina, Weiler-Normann, Christina, Schramm, Christoph, Donato, Maria Francesca, Lohse, Ansgar, Andrade, Raul J., Patwardhan, Vilas R., van Hoek, Bart, Biewenga, Maaike, Kremer, Andreas E., Ueda, Yoshihide, Deneau, Mark, Pedersen, Mark, Mayo, Marlyn J., Floreani, Annarosa, Burra, Patrizia, Secchi, Maria Francesca, Beretta-Piccoli, Benedetta Terziroli, Sciveres, Marco, Maggiore, Giuseppe, Jafri, Syed-Mohammed, Debray, Dominique, Girard, Muriel, Lacaille, Florence, Lytvyak, Ellina, Mason, Andrew L., Heneghan, Michael, and Oo, Ye Htun

Published
2022
Full Text
View/download PDF

22. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group

Author

Almasio, P., Alvarez, F., Andrade, R., Arikan, C., Assis, D., Bardou-Jacquet, E., Biewenga, M., Cancado, E., Cazzagon, N., Chazouillères, O., Colloredo, G., Cuarterolo, M., Dalekos, G., Debray, D., Robles-Díaz, M., Drenth, J., Dyson, J., Efe, C., Engel, B., Ferri, S., Fontana, R., Gatselis, N., Gerussi, A., Halilbasic, E., Halliday, N., Heneghan, M., Hirschfield, G., van Hoek, B., Hørby Jørgensen, M., Indolfini, G., Iorio, R., Jeong, S., Jones, D., Kelly, D., Kerkar, N., Lacaille, F., Lammert, C., Leggett, B., Lenzi, M., Levy, C., Liberal, R., Lleo, A., Lohse, A., Ines Lopez, S., de Martin, E., McLin, V., Mieli-Vergani, G., Milkiewicz, P., Mohan, N., Muratori, L., Nebbia, G., van Nieuwkerk, C., Oo, Y., Ortega, A., Páres, A., Pop, T., Pratt, D., Purnak, T., Ranucci, G., Rushbrook, S., Schramm, C., Stättermayer, A., Swain, M., Tanaka, A., Taubert, R., Terrabuio, D., Terziroli, B., Trauner, M., Valentino, P., van den Brand, F., Villamil, A., Wahlin, S., Ytting, H., Zachou, K., Zeniya, M., Pape, Simon, Snijders, Romée J.A.L.M., Gevers, Tom J.G., Chazouilleres, Oliver, Dalekos, George N., Hirschfield, Gideon M., Lenzi, Marco, Trauner, Michael, Manns, Michael P., Vierling, John M., Montano-Loza, Aldo J., Lohse, Ansgar W., Schramm, Christoph, Drenth, Joost P.H., and Heneghan, Michael A.

Published
2022
Full Text
View/download PDF

23. Patient and Caregiver Attitudes and Practices of Exercise in Candidates Listed for Liver Transplantation

Author

Chascsa, David M, Lai, Jennifer C, Dunn, Michael A, Montano-Loza, Aldo J, Kappus, Matthew R, Dasarathy, Srinivasan, and Carey, Elizabeth J

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Behavioral and Social Science, Rehabilitation, Transplantation, Digestive Diseases, Organ Transplantation, Attitude to Health, Caregivers, Exercise, Exercise Tolerance, Fatigue, Female, Health Surveys, Humans, Liver Diseases, Liver Transplantation, Male, Outpatients, Physical Fitness, Preoperative Period, United States, Physical capacity, Liver transplantation, Patient, Caregiver, Gastroenterology & Hepatology, Clinical sciences
Abstract

BackgroundImpaired physical capacity increases peri-liver transplant complications. Patient perceptions regarding exercise prior to transplantation are not known.AimsThis study aimed to assess patient and caregiver activity levels, perceptions of willingness to exercise, and of provider advice.MethodsConsecutive patients listed for liver transplant and caregivers presenting for routine outpatient visits were evaluated over a 3-month interval. Anonymous surveys adapted to patients and caregivers addressed the importance and safety of exercise, type and duration of exercise performed, barriers, willingness to wear a monitoring device, and perceived provider recommendations. Responses were logged on a Likert scale from 1 to 5.ResultsThree hundred and sixty-eight responses were received. Most participants perceived exercise as important. Patients exercised three times per week for 30 min. Eighty percent endorsed walking (median response: 2-agree; IQR 1-2). Most did not jog, swim, cycle, or strength train. Fatigue, reported by 70%, was the major barrier (2, IQR 1-3). Over 90% of caregivers endorsed exercise as important (1-strongly agree, IQR 1-2) and encouraged exercise (median response 2, IQR 1-2). Over 60% of patients (median response 2, IQR 1-3) and caregivers (median response 2, IQR 2-3) felt providers encouraged exercise.ConclusionsPatients and caregivers are willing to exercise to optimize physical fitness prior to liver transplantation.

Published
2018

24. Poor performance of psoas muscle index for identification of patients with higher waitlist mortality risk in cirrhosis

Author

Ebadi, Maryam, Wang, Connie W, Lai, Jennifer C, Dasarathy, Srinivasan, Kappus, Matthew R, Dunn, Michael A, Carey, Elizabeth J, Montano‐Loza, Aldo J, and From the Fitness, Life Enhancement

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Liver Disease, Digestive Diseases, Good Health and Well Being, Aged, Biomarkers, Comorbidity, Female, Humans, Kaplan-Meier Estimate, Liver Cirrhosis, Liver Transplantation, Male, Middle Aged, Organ Size, Prognosis, Psoas Muscles, Risk Assessment, Risk Factors, Sex Factors, Tomography, X-Ray Computed, Sarcopenia, Computed tomography, End-stage liver disease, From the Fitness, Life Enhancement, and Exercise in Liver Transplantation (FLEXIT) Consortium, Physiology, Human Movement and Sports Sciences, Clinical sciences, Allied health and rehabilitation science, Sports science and exercise
Abstract

BackgroundSarcopenia, characterized by low muscle mass, associates with mortality in patients with cirrhosis. Skeletal muscle area in a single computed tomography image at the level of the third lumbar vertebrate (L3) is a valid representative of whole body muscle mass. Controversy remains regarding applicability of psoas muscle to identify patients at greater risk of mortality. We aimed to determine psoas muscle index (PMI) association with skeletal muscle index (SMI) and to evaluate the capacity of PMI to predict liver transplant waitlist mortality.MethodsWe evaluated listed adult patients with cirrhosis from 2012 to 2013 at four North American liver transplant centres. From L3 computed tomography images within 3 months of listing, we determined SMI and PMI expressed by cm2 /m2 . Low SMI was defined as SMI  0.7, P

Published
2018

26. OS-015 Time to complete biochemical response and disease progression in autoimmune hepatitis

Author

Baven-Pronk, Martine A.M.C., primary, Slooter, Charlotte, additional, Lleo, Ana, additional, Colapietro, Francesca, additional, Lenzi, Marco, additional, Muratori, Paolo, additional, Kerkar, Nanda, additional, Dalekos, George, additional, Zachou, Kalliopi, additional, Lucena, Maria Isabel, additional, Robles-Díaz, Mercedes, additional, Di Zeo-Sánchez, Daniel E., additional, Andrade, Raul J., additional, Montano-Loza, Aldo J, additional, Lytvyak, Ellina, additional, Lissenberg-Witte, Birgitte, additional, Maisonneuve, Patrick, additional, Bouma, Gerd, additional, Macedo, Guilherme, additional, Liberal, Rodrigo, additional, Tushuizen, Maarten, additional, Drenth, Joost PH, additional, de Boer, Ynto, additional, and van Hoek, Bart, additional

Published
2024
Full Text
View/download PDF

27. THU-111 Second-line treatment in recurrent primary biliary cholangitis after liver transplantation: an international multicentre study

Author

Abbas, Nadir, primary, Mladenovic, Rebecca, additional, Lytvyak, Ellina, additional, Halliday, Neil, additional, Thorburn, Douglas, additional, Chung, Yooyun, additional, Joshi, Deepak, additional, Heneghan, Michael, additional, Dyson, Jessica, additional, Jones, David E., additional, Corpechot, Christophe, additional, Montano-Loza, Aldo J, additional, and Trivedi, Palak J., additional

Published
2024
Full Text
View/download PDF

28. TOP-169 Sex, ethnicity and clinical outcomes in autoimmune hepatitis: results from a large multicenter longitudinal cohort

Author

Lytvyak, Ellina, primary, Shreekumar, Devika, additional, Hirschfield, Gideon M., additional, Plagiannakos, Christina, additional, Ko, Hin HIn, additional, Swain, Mark G, additional, Hercun, Julian, additional, Worobetz, Lawrence, additional, Vincent, Catherine, additional, Flemming, Jennifer, additional, Qumosani, Karim, additional, Chen, Tianyan, additional, Grbic, Dusanka, additional, Cheung, Angela, additional, Umar, Narmeen, additional, Iqbal, Iffat, additional, Cameron, Madeline, additional, Gulamhusein, Aliya, additional, Mason, Andrew L., additional, Hansen, Bettina, additional, and Montano-Loza, Aldo J, additional

Published
2024
Full Text
View/download PDF

29. LBP-039 Oral alpha-v/beta-6 and alpha-v/beta-1 integrin inhibitor bexotegrast in primary sclerosing cholangitis: updated 12-week interim safety and efficacy analysis of the INTEGRIS-PSC phase 2a trial

Author

Trauner, Michael, primary, Kowdley, Kris V., additional, Hirschfield, Gideon M., additional, Lefebvre, Eric, additional, Decaris, Martin, additional, Schaub, Johanna, additional, Clark, Annie, additional, Lin, Mandy, additional, An, Mahru, additional, Balasubramanyam, Aarthi, additional, Barnes, Chris N., additional, Pencek, Richard, additional, Thorburn, Douglas, additional, Montano-Loza, Aldo J., additional, Bowlus, Christopher L., additional, Schramm, Christoph, additional, Levy, Cynthia, additional, and Trivedi, Palak J., additional

Published
2024
Full Text
View/download PDF

30. THU-098 Appraising gain of an extended 2-year placebo-controlled trial in primary biliary cholangitis: challenges for evaluating clinical outcomes

Author

Hansen, Bettina E., primary, Hirschfield, Gideon M., additional, Perez, Carla Fiorella Murillo, additional, McWherter, Charles A., additional, Dickinson, Klara, additional, Mason, Andrew L., additional, Montano-Loza, Aldo J, additional, Lytvyak, Ellina, additional, Dalekos, George, additional, Gatselis, Nikolaos, additional, Nevens, Frederik, additional, Cazzagon, Nora, additional, Levy, Cynthia, additional, Abbas, Nadir, additional, Trivedi, Palak, additional, Thorburn, Douglas, additional, Bonder, Alan, additional, Patwardhan, Vilas, additional, Londoño, María Carlota, additional, Carbone, Marco, additional, Cristoferi, Laura, additional, van der Meer, Adriaan J., additional, de Veer, Rozanne C., additional, Tanaka, Atsushi, additional, Janssen, Harry L.A., additional, Zigmond, Ehud, additional, Yehezkel, Eyal, additional, Kremer, Andreas E., additional, Deibel, Ansgar, additional, Bruns, Tony, additional, Große, Karsten, additional, Kowdley, Kris V., additional, Lleo, Ana, additional, Mayo, Marlyn J., additional, Verhelst, Xavier, additional, and Corpechot, Christophe, additional

Published
2024
Full Text
View/download PDF

31. FRI-122 Decompensated cirrhosis is associated with disruption of nuclear positioning in skeletal muscle and selective atrophy of type II myofibers

Author

Montano-Loza, Aldo J, primary, Motamedrad, Maryam, additional, Ebadi, Maryam, additional, Sanchez-Fernandez, Norberto, additional, Parente, Alessandro, additional, Dunichand-Hoedl, Abha, additional, Rider, Elora, additional, Kneteman, Norman, additional, Shapiro, James, additional, Bigam, David, additional, Dajani, Khaled, additional, Anderson, Blaire, additional, Baracos, Vickie, additional, and C. Mazurak, Vera, additional

Published
2024
Full Text
View/download PDF

32. OS-018 Liver stiffness measurement by vibration-controlled transient elastography predicts adverse clinical outcomes in autoimmune hepatitis: results from a large multicenter longitudinal study

Author

Lytvyak, Ellina, primary, Umar, Narmeen, additional, Hirschfield, Gideon M., additional, Plagiannakos, Christina, additional, Ko, Hin HIn, additional, Swain, Mark G, additional, Hercun, Julian, additional, Worobetz, Lawrence, additional, Vincent, Catherine, additional, Flemming, Jennifer, additional, Qumosani, Karim, additional, Chen, Tianyan, additional, Grbic, Dusanka, additional, Cheung, Angela, additional, Shreekumar, Devika, additional, Iqbal, Iffat, additional, Cameron, Madeline, additional, Gulamhusein, Aliya, additional, Mason, Andrew L., additional, Hansen, Bettina, additional, and Montano-Loza, Aldo J, additional

Published
2024
Full Text
View/download PDF

33. SAT-021 Recurrence of autoimmune hepatitis cholestatic variant syndromes after liver transplantation affects graft and patient survival in an international multicentre cohort

Author

Ronca, Vincenzo, primary, Parente, Alessandro, additional, Lytvyak, Ellina, additional, Hansen, Bettina, additional, Hirschfield, Gideon M., additional, Bonder, Alan, additional, Ebadi, Maryam, additional, Elwir, Saleh, additional, Alsaed, Mohamad, additional, Milkiewicz, Piotr, additional, Janik, Maciej, additional, Marschall, Hanns-Ulrich, additional, Burza, Maria Antonella, additional, Efe, Cumali, additional, Caliskan, Ali Riza, additional, Harputluoglu, Murat, additional, Kabaçam, Gökhan, additional, Terrabuio, Debora Raquel, additional, Onofrio, Fernanda, additional, Selzner, Nazia, additional, Pares, Albert, additional, Llovet, Laura Patricia, additional, Akyildiz, Murat, additional, Arıkan, Cigdem, additional, Manns, Michael P., additional, Taubert, Richard, additional, Weber, Anna-Lena, additional, Schiano, Thomas, additional, Haydel, Brandy, additional, Czubkowski, Piotr, additional, Socha, Piotr, additional, Ołdak, Natalia, additional, Akamatsu, Nobuhisa, additional, Tanaka, Atsushi, additional, Levy, Cynthia, additional, Martin, Eric F., additional, Goel, Aparna, additional, Sedki, Mai, additional, Jankowska, Irena, additional, Ikegami, Toru, additional, Rodriguez, Maria, additional, Sterneck, Martina, additional, Weiler-Normann, Christina, additional, Schramm, Christoph, additional, Donato, Maria Francesca, additional, Lohse, Ansgar W., additional, Andrade, Raul J., additional, Patwardhan, Vilas, additional, van Hoek, Bart, additional, Biewenga, Maaike, additional, Kremer, Andreas, additional, Ueda, Yoshihide, additional, Deneau, Mark, additional, Pedersen, Mark, additional, Mayo, Marlyn J., additional, Floreani, Annarosa, additional, Burra, Patrizia, additional, Secchi, Maria Francesca, additional, Terziroli, Benedetta, additional, Sciveres, Marco, additional, Maggiore, Giuseppe, additional, Jafri, Syed-Mohammed, additional, Debray, Dominique, additional, Girard, Muriel, additional, Lacaille, Florence, additional, Heneghan, Michael, additional, Mason, Andrew L., additional, Oo, Ye Htun, additional, and Montano-Loza, Aldo J., additional

Published
2024
Full Text
View/download PDF

36. A multicenter study to define sarcopenia in patients with end‐stage liver disease

Author

Carey, Elizabeth J, Lai, Jennifer C, Wang, Connie W, Dasarathy, Srinivasan, Lobach, Iryna, Montano‐Loza, Aldo J, Dunn, Michael A, and for the Fitness, Life Enhancement

Subjects
Organ Transplantation, Clinical Research, Transplantation, Digestive Diseases, Liver Disease, Rare Diseases, Good Health and Well Being, End Stage Liver Disease, Female, Humans, Male, Middle Aged, Retrospective Studies, Sarcopenia, Sex Factors, United States, Fitness, Life Enhancement, and Exercise in Liver Transplantation Consortium, Clinical Sciences, Surgery
Abstract

Sarcopenia is associated with increased wait-list mortality, but a standard definition is lacking. In this retrospective study, we sought to determine the optimal definition of sarcopenia in end-stage liver disease (ESLD) patients awaiting liver transplantation (LT). Included were 396 patients newly listed for LT in 2012 at 5 North American transplant centers. All computed tomography scans were read by 2 individuals with interobserver correlation of 98%. Using image analysis software, the total cross-sectional area (cm2 ) of abdominal skeletal muscle at the third lumbar vertebra was measured. The skeletal muscle index (SMI), which normalizes muscle area to patient height, was then calculated. The primary outcome was wait-list mortality, defined as death on the waiting list or removal from the waiting list for reasons of clinical deterioration. Sex-specific potential cutoff values to define sarcopenia were determined with a grid search guided by log-rank test statistics. Optimal search methods identified potential cutoffs to detect survival differences between groups. The overall median SMI was 47.6 cm2 /m2 : 50.0 in men and 42.0 in women. At a median of 8.8 months follow-up, mortality was 25% in men and 36% in women. Patients who died had lower SMI than those who survived (45.6 versus 48.5 cm2 /m2 ; P

Published
2017

37. Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: First report of the IAIHG retrospective registry

Author

MS MDL 1, Cancer, Infection & Immunity, Slooter, Charlotte D., Van Den Brand, Floris F., Lleo, Ana, Colapietro, Francesca, Lenzi, Marco, Muratori, Paolo, Kerkar, Nanda, Dalekos, G., Zachou, Kalliopi, Lucena, M. Isabel, Robles-Díaz, Mercedes, Di Zeo-Sánchez, Daniel E., Andrade, Raúl J., Montano-Loza, Aldo J., Lytvyak, Ellina, Lissenberg-Witte, Birgit I., Maisonneuve, Patrick, Bouma, Gerd, MacEdo, Guilherme, Liberal, Rodrigo, De Boer, Ynto S., Van Erpecum, K., Dutch AIH Study Group, International Autoimmune Hepatitis Group, MS MDL 1, Cancer, Infection & Immunity, Slooter, Charlotte D., Van Den Brand, Floris F., Lleo, Ana, Colapietro, Francesca, Lenzi, Marco, Muratori, Paolo, Kerkar, Nanda, Dalekos, G., Zachou, Kalliopi, Lucena, M. Isabel, Robles-Díaz, Mercedes, Di Zeo-Sánchez, Daniel E., Andrade, Raúl J., Montano-Loza, Aldo J., Lytvyak, Ellina, Lissenberg-Witte, Birgit I., Maisonneuve, Patrick, Bouma, Gerd, MacEdo, Guilherme, Liberal, Rodrigo, De Boer, Ynto S., Van Erpecum, K., Dutch AIH Study Group, and International Autoimmune Hepatitis Group

Published
2024

38. Treatment response and clinical event-free survival in autoimmune hepatitis:A Canadian multicentre cohort study

Author

Plagiannakos, Christina G., Hirschfield, Gideon M., Lytvyak, Ellina, Roberts, Surain B., Ismail, Marwa, Gulamhusein, Aliya F., Selzner, Nazia, Qumosani, Karim M., Worobetz, Lawrence, Hercun, Julian, Vincent, Catherine, Flemming, Jennifer A., Swain, Mark G., Cheung, Angela, Chen, Tianyan, Grbic, Dusanka, Peltekain, Kevork, Mason, Andrew L., Montano-Loza, Aldo J., Hansen, Bettina E., Plagiannakos, Christina G., Hirschfield, Gideon M., Lytvyak, Ellina, Roberts, Surain B., Ismail, Marwa, Gulamhusein, Aliya F., Selzner, Nazia, Qumosani, Karim M., Worobetz, Lawrence, Hercun, Julian, Vincent, Catherine, Flemming, Jennifer A., Swain, Mark G., Cheung, Angela, Chen, Tianyan, Grbic, Dusanka, Peltekain, Kevork, Mason, Andrew L., Montano-Loza, Aldo J., and Hansen, Bettina E.

Abstract

Background & Aims: Treatment outcomes for people living with autoimmune hepatitis (AIH) are limited by a lack of specific therapies, as well as limited well-validated prognostic tools and clinical trial endpoints. We sought to identify predictors of outcome for people living with AIH. Methods: We evaluated the clinical course of people with AIH across 11 Canadian centres. Biochemical changes were analysed using linear mixed-effect and logistic regression. Clinical outcome was dynamically modelled using time-varying Cox proportional hazard modelling and landmark analysis. Results: In 691 patients (median age 49 years, 75.4% female), with a median follow-up of 6 years (25th-75th percentile, 2.5-11), 118 clinical events occurred. Alanine aminotransferase (ALT) normalisation occurred in 63.8% of the cohort by 12 months. Older age at diagnosis (odd ratio [OR] 1.19, 95% CI 1.06-1.35) and female sex (OR 1.94, 95% CI 1.18-3.19) were associated with ALT normalisation at 6 months, whilst baseline cirrhosis status was associated with reduced chance of normalisation at 12 months (OR 0.52, 95% CI 0.33-0.82). Baseline total bilirubin, aminotransferases, and IgG values, as well as initial prednisone dose, did not predict average ALT reduction. At baseline, older age (hazard ratio [HR] 1.25, 95% CI 1.12-1.40), cirrhosis at diagnosis (HR 3.67, 95% CI 2.48-5.43), and elevated baseline total bilirubin (HR 1.36, 95% CI 1.17-1.58) increased the risk of clinical events. Prolonged elevations in ALT (HR 1.07, 95% CI 1.00-1.13) and aspartate aminotransferase (HR 1.13, 95% CI 1.06-1.21), but not IgG (HR 1.01, 95% CI 0.95-1.07), were associated with higher risk of clinical events. Higher ALT at 6 months was associated with worse clinical event-free survival. Conclusion: In people living with AIH, sustained elevated aminotransferase values, but not IgG, are associated with poorer long-term outcomes. Biochemical

Published
2024

39. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis

Author

Corpechot, Christophe, Chazouillères, Olivier, Belnou, Pierre, Montano-Loza, Aldo J., Mason, Andrew, Ebadi, Maryam, Eurich, Dennis, Chopra, Sascha, Jacob, Dietmar, Schramm, Christoph, Sterneck, Martina, Bruns, Tony, Reuken, Philipp, Rauchfuss, Falk, Roccarina, Davide, Thorburn, Douglas, Gerussi, Alessio, Trivedi, Palak, Hirschfield, Gideon, McDowell, Patrick, Nevens, Frederik, Boillot, Olivier, Bosch, Alexie, Giostra, Emiliano, Conti, Filomena, Poupon, Raoul, Parés, Albert, Reig, Anna, Donato, Maria Francesca, Malinverno, Federica, Floreani, Annarosa, Russo, Francesco Paolo, Cazzagon, Nora, Verhelst, Xavier, Goet, Jorn, Harms, Maren, van Buuren, Henk, Hansen, Bettina, Carrat, Fabrice, and Dumortier, Jérôme

Published
2020
Full Text
View/download PDF

43. Perspective: improving vitamin D status in the management of COVID-19

Author

Ebadi, Maryam and Montano-Loza, Aldo J.

Subjects
Alfacalcidol -- Health aspects, Calcifediol -- Health aspects, Vitamin D -- Health aspects, Coronaviruses -- Health aspects, Food/cooking/nutrition, Health
Abstract

Author(s): Maryam Ebadi [sup.1], Aldo J. Montano-Loza [sup.1] Author Affiliations: (1) Division of Gastroenterology & Liver Unit, University of Alberta Hospital, Edmonton, Canada Introduction A novel coronavirus disease 2019 (COVID-19) [...]

Published
2020
Full Text
View/download PDF

45. Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group

Author

Than, Nwe Ni, Hodson, James, Schmidt-Martin, Daniel, Taubert, Richard, Wawman, Rebecca E., Botter, Meemee, Gautam, Nishant, Bock, Kilian, Jones, Rebecca, Appanna, Gautham D, Godkin, Andrew, Montano-Loza, Aldo J., Lammert, Frank, Schramm, Christoph, Manns, Michael P., Swain, Mark, Burak, Kelly W., Adams, David H., Hirschfield, Gideon M, and Oo, Ye Htun

Published
2019
Full Text
View/download PDF

48. Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival

Author

Montano-Loza, Aldo J., Hansen, Bettina E., Corpechot, Christophe, Roccarina, Davide, Thorburn, Douglas, Trivedi, Palak, Hirschfield, Gideon, McDowell, Patrick, Poupon, Raoul, Dumortier, Jerome, Bosch, Alexie, Giostria, Emiliano, Conti, Filomena, Parés, Albert, Reig, Anna, Floreani, Annarosa, Russo, Francesco Paolo, Goet, Jorn C., Harms, Maren H., van Buuren, Henk, Van den Ende, Natalie, Nevens, Frederik, Verhelst, Xavier, Donato, Maria Francesca, Malinverno, Federica, Ebadi, Maryam, and Mason, Andrew L.

Published
2019
Full Text
View/download PDF

49. Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis

Author

Colapietro, Francesca, primary, Maisonneuve, Patrick, additional, Lytvyak, Ellina, additional, Beuers, Ulrich, additional, Verdonk, Robert C., additional, van der Meer, Adriaan J., additional, van Hoek, Bart, additional, Kuiken, Sjoerd D., additional, Brouwer, Johannes T., additional, Muratori, Paolo, additional, Aghemo, Alessio, additional, Carella, Francesco, additional, van den Berg, Ad P., additional, Zachou, Kalliopi, additional, Dalekos, George N., additional, Di Zeo-Sánchez, Daniel E., additional, Robles, Mercedes, additional, Andrade, Raul J., additional, Montano-Loza, Aldo J., additional, van den Brand, Floris F., additional, Slooter, Charlotte D., additional, Macedo, Guilherme, additional, Liberal, Rodrigo, additional, de Boer, Ynto S., additional, Lleo, Ana, additional, van Gerven, N., additional, van Erpecum, K., additional, Ouden, J den, additional, Brouwer, J., additional, Vrolijk, J., additional, Gevers, T.J., additional, Drenth, J., additional, Guichelaar, M., additional, Bouma, G., additional, Schreuder, T.C.M.A., additional, van der Wouden, E.J., additional, Baak, L.C., additional, Stadhouders, P., additional, Klemt-Kropp, M., additional, Verhagen, M., additional, Bhalla, A., additional, Kuijvenhoven, J., additional, Almasio, P., additional, Alvarez, F., additional, Andrade, R., additional, Arikan, C., additional, Assis, D., additional, Bardou-Jacquet, E., additional, Biewenga, M., additional, Cancado, E., additional, Cazzagon, N., additional, Chazouillères, O., additional, Colloredo, G., additional, Cuarterolo, M., additional, Dalekos, G., additional, Debray, D., additional, Robles-Díaz, M., additional, Dyson, J., additional, Efe, C., additional, Engel, B., additional, Ferri, S., additional, Fontana, R., additional, Gatselis, N., additional, Gerussi, A., additional, Halilbasic, E., additional, Halliday, N., additional, Heneghan, M., additional, Hirschfield, G., additional, van Hoek, B., additional, Hørby Jørgensen, M., additional, Indolfini, G., additional, Iorio, R., additional, Invernizzi, P., additional, Jeong, S., additional, Jones, D., additional, Kelly, D., additional, Kerkar, N., additional, Lacaille, F., additional, Lammert, C., additional, Leggett, B., additional, Lenzi, M., additional, Levy, C., additional, Liberal, R., additional, Lleo, A., additional, Lohse, A., additional, Lopez, S. Ines, additional, de Martin, E., additional, McLin, V., additional, Mieli-Vergani, G., additional, Milkiewicz, P., additional, Mohan, N., additional, Muratori, L., additional, Nebbia, G., additional, van Nieuwkerk, C., additional, Oo, Y., additional, Ortega, A., additional, Páres, A., additional, Pop, T., additional, Pratt, D., additional, Purnak, T., additional, Ranucci, G., additional, Rushbrook, S., additional, Schramm, C., additional, Stättermayer, A., additional, Swain, M., additional, Tanaka, A., additional, Taubert, R., additional, Terrabuio, D., additional, Terziroli, B., additional, Trauner, M., additional, Valentino, P., additional, van den Brand, F., additional, Vergani, D., additional, Villamil, A., additional, Wahlin, S., additional, Ytting, H., additional, Zachou, K., additional, and Zeniya, M., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results